Aytu Biopharma Inc
NASDAQ:AYTU

Watchlist Manager
Aytu Biopharma Inc Logo
Aytu Biopharma Inc
NASDAQ:AYTU
Watchlist
Price: 2.9 USD 4.69% Market Closed
Market Cap: 29.6m USD

Operating Margin
Aytu Biopharma Inc

1.9%
Current
-12%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1.9%
=
Operating Profit
1.2m
/
Revenue
63.7m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Aytu Biopharma Inc
NASDAQ:AYTU
28.7m USD
2%
US
Eli Lilly and Co
NYSE:LLY
997.6B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
494.8B USD
27%
CH
Roche Holding AG
SIX:ROG
263.6B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
218.4B GBP
24%
CH
Novartis AG
SIX:NOVN
214.5B CHF
33%
US
Merck & Co Inc
NYSE:MRK
270.7B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
146.1B USD
29%
No Stocks Found

Aytu Biopharma Inc
Glance View

Market Cap
28.7m USD
Industry
Pharmaceuticals

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 175 full-time employees. The company went IPO on 2017-10-20. The firm markets a portfolio of prescription products addressing primary care and pediatric markets. The firm's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The firm's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

AYTU Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1.9%
=
Operating Profit
1.2m
/
Revenue
63.7m
What is the Operating Margin of Aytu Biopharma Inc?

Based on Aytu Biopharma Inc's most recent financial statements, the company has Operating Margin of 1.9%.

Back to Top